# Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

> **NCT05166577** · PHASE1 · TERMINATED · sponsor: **Viracta Therapeutics, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma
- EBV-Related Gastric Carcinoma
- EBV-Related Leiomyosarcoma
- EBV Related Carcinoma
- EBV-Related Sarcoma

## Interventions

- **DRUG:** Nanatinostat
- **DRUG:** Valganciclovir
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05166577
- **Lead sponsor:** Viracta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-08
- **Primary completion:** 2024-10-30
- **Final completion:** 2025-01-10
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05166577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05166577, "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05166577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*